Merck’s Early PD-1/VEGF Data Competitive in Lung Cancer, but Summit ‘Looms Large’

Why It Matters

The trial results could reshape the competitive hierarchy in the fast‑growing PD‑1/VEGF bispecific market, influencing Merck’s revenue outlook and investors’ confidence as the FDA evaluates rival candidates.

Key Takeaways

• MK-2010 shows 55% ORR in treatment‑naïve NSCLC patients
• Second‑line ORR for MK-2010 is 44%, comparable to ivonescimab
• Summit’s ivonescimab holds FDA review, seen as “Keytruda‑killer.”
• Merck’s deal totals $588M upfront, up to $2.7B milestones
• Analysts demand survival data to prove MK-2010’s competitive edge

Pulse Analysis

The emergence of PD‑1/VEGF bispecific antibodies marks a pivotal shift in immuno‑oncology, aiming to simultaneously block tumor immune evasion and angiogenesis. Merck’s MK‑2010 joins a small but growing cohort of candidates that target both pathways, offering a theoretical advantage over monotherapy checkpoint inhibitors. Early-phase response rates, especially the 55% observed in first‑line NSCLC, signal that the molecule can generate meaningful tumor shrinkage, a prerequisite for advancing to pivotal trials and securing market share.

Competitive pressure intensifies as Summit Therapeutics and China’s Akeso push ivonescimab through the FDA pipeline. With a Phase 3 overall response rate near 50% and a reputation as a “Keytruda‑killer,” ivonescimab sets a high benchmark that analysts use to gauge MK‑2010’s potential. The FDA’s pending decision on ivonescimab’s chemotherapy combo adds regulatory uncertainty, but also underscores the appetite for bispecifics in the NSCLC arena. Investors are closely watching whether Merck can translate its early efficacy signals into durable survival benefits that differentiate it from the Summit/Akeso platform.

Strategically, Merck’s partnership structure provides both financial muscle and development flexibility. The $588 million upfront payment to LaNova, coupled with up to $2.7 billion in milestones and a subsequent $951 million infusion from Sino Biopharmaceutical, equips Merck to explore combination regimens, including antibody‑drug conjugates that could further enhance efficacy. Should later‑stage trials confirm the early response data and demonstrate survival gains, MK‑2010 could become a cornerstone of Merck’s oncology portfolio, offsetting competitive threats and reinforcing its leadership in cancer therapeutics.